Bell TJ et al. The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35-42
Andresen V et al. The patient burden of opioid-induced constipation: New insights from a large, multinational survey in five European countries. UEG Journal. 2018;6(8):1254-1266.
DGS -Praxisleitlinie „Opioidinduzierte Obstipation“ https://dgs-praxisleitlinie.de/opioidinduzierte Obstipation abgerufen 14.1.2026
Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835-842.
Poulsen JL, et al. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem Clin Exp Gastroenterol. 2014;7:345-358.
Brock C et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-1865.
Fachinformation Moventig^® 12,5 mg/25 mg Filmtabletten, Stand 10/2024.
Pergolizzi JV et al The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety, Drug Design, Development and Therapy 2020:14 1009–1025.
Camilleri M, et al. Neurogastroenterol Motil. 2014;26(10):1386-95.
Poulsen JL, et al. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem Clin Exp Gastroenterol. 2014;7:345-358.